flecainide has been researched along with Tachycardia, Ventricular in 134 studies
Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.
flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).
Tachycardia, Ventricular: An abnormally rapid ventricular rhythm usually in excess of 150 beats per minute. It is generated within the ventricle below the BUNDLE OF HIS, either as autonomic impulse formation or reentrant impulse conduction. Depending on the etiology, onset of ventricular tachycardia can be paroxysmal (sudden) or nonparoxysmal, its wide QRS complexes can be uniform or polymorphic, and the ventricular beating may be independent of the atrial beating (AV dissociation).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this review is to evaluate the available data on efficacy and safety of flecainide in all the spectrum of its indications including cardioversion of recent-onset AF, sinus rhythm maintenance in paroxysmal AF and management of ventricular tachyarrhythmias." | 8.89 | Flecainide acetate for the treatment of atrial and ventricular arrhythmias. ( Apostolakis, S; Breithardt, G; Fabritz, L; Kirchhof, P; Oeff, M; Tebbe, U, 2013) |
| "Thirty-three patients received flecainide because of exercise-induced ventricular arrhythmias despite conventional (for different reasons, not always optimal) therapy (median age 25 years; range 7 to 68 years; 73% female)." | 7.77 | Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. ( Bhuiyan, ZA; Fish, FA; Haïssaguerre, M; Kannankeril, PJ; Knollmann, BC; Krahn, AD; Laborderie, J; Leenhardt, A; Sacher, F; Shimizu, W; Sumitomo, N; van der Veen, MJ; van der Werf, C; Viskin, S; Watanabe, H; Wilde, AA; Willems, AR, 2011) |
| "A 37-year-old man with symptomatic acute atrial fibrillation and a low-voltage electrocardiogram was treated with flecainide intravenously." | 7.73 | [Life-threatening ventricular tachycardia during flecainide treatment for symptomatic atrial fibrillation in a patient with a structural cardiac disorder]. ( Rienstra, M; van Gelder, IC; van Veldhuisen, DJ; Wiesfeld, AC, 2006) |
| "The flecainide test is widely used in Brugada syndrome." | 7.72 | Flecainide test in Brugada syndrome: a reproducible but risky tool. ( Ceriotti, C; Galimberti, P; Gasparini, M; Mantica, M; Napolitano, C; Priori, SG; Simonini, S, 2003) |
| "The Cardiac Arrhythmia Suppression Trial has shown that flecainide was associated with an increased incidence of sudden cardiac death in postinfarction patients." | 7.69 | Reentrant arrhythmias in the subacute infarction period. The proarrhythmic effect of flecainide acetate on functional reentrant circuits. ( Assadi, MA; Avitable, MJ; Caref, EB; el-Sherif, N; Isber, N; Ndrepepa, G; Patel, AI; Restivo, M; Yin, H, 1995) |
| "This study suggests that flecainide and beta-blockers association is complementary to implantable cardioverter-defibrillator and catheter ablation and is safe for treating persistent symptomatic VA in patients with ARVC." | 5.72 | Safety and efficacy of flecainide associated with beta-blockers in arrhythmogenic right ventricular cardiomyopathy. ( Badenco, N; Duthoit, G; Frank, R; Gandjbakhch, E; Hidden-Lucet, F; Himbert, C; Laredo, M; Maupain, C; Rolland, T; Waintraub, X, 2022) |
| "No evidence of ischemic heart disease was detected." | 5.30 | Class IC antiarrhythmic drugs, flecainide and pilsicainide, produce ST segment elevation simulating inferior myocardial ischemia. ( Ito, H; Nakamura, W; Segawa, K; Tanaka, S; Yoshimoto, N, 1998) |
| "This report presents the case of a young man of 24 years old with Asperger syndrome who ingest quantities of medication whose flecainide." | 5.05 | [Flecainid intoxication: Evolution, complications and care of]. ( Bensussan, H; Mhamdi, K, 2020) |
| "The aim of this review is to evaluate the available data on efficacy and safety of flecainide in all the spectrum of its indications including cardioversion of recent-onset AF, sinus rhythm maintenance in paroxysmal AF and management of ventricular tachyarrhythmias." | 4.89 | Flecainide acetate for the treatment of atrial and ventricular arrhythmias. ( Apostolakis, S; Breithardt, G; Fabritz, L; Kirchhof, P; Oeff, M; Tebbe, U, 2013) |
| "Flecainide is a class Ic antidysrhythmic agent used to prevent and treat both ventricular and supraventricular tachycardias, including atrial fibrillation, atrioventricular nodal re-entrant tachycardia, and Wolff-Parkinson-White syndrome." | 3.96 | The Case of Flecainide Toxicity: What to Look for and How to Treat. ( Newson, JM; Santos, CD; Todd, BR; Walters, BL, 2020) |
| " Her pregnancy was uncomplicated, and she was medically managed with metoprolol, flecainide, and verapamil." | 3.96 | Catecholaminergic polymorphic ventricular tachycardia in pregnancy: a case report. ( Contag, S; Schumer, A, 2020) |
| "Dronedarone was the only anti-arrhythmic drug with significantly lower risk for arrhythmic death, sustained ventricular arrhythmia or ICD implantation than sotalol among patients with atrial fibrillation." | 3.88 | Ventricular arrhythmia and death among atrial fibrillation patients using anti-arrhythmic drugs. ( Friberg, L, 2018) |
| "Antiarrhythmic agents which belong to class Ia (quinidine) and Ic (flecainide) reportedly increase propensity to ventricular tachyarrhythmia, whereas class Ib agents (lidocaine and mexiletine) are recognized as safe antiarrhythmics." | 3.80 | Effects of Na+ channel blockers on extrasystolic stimulation-evoked changes in ventricular conduction and repolarization. ( Osadchii, OE, 2014) |
| "Thirty-three patients received flecainide because of exercise-induced ventricular arrhythmias despite conventional (for different reasons, not always optimal) therapy (median age 25 years; range 7 to 68 years; 73% female)." | 3.77 | Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. ( Bhuiyan, ZA; Fish, FA; Haïssaguerre, M; Kannankeril, PJ; Knollmann, BC; Krahn, AD; Laborderie, J; Leenhardt, A; Sacher, F; Shimizu, W; Sumitomo, N; van der Veen, MJ; van der Werf, C; Viskin, S; Watanabe, H; Wilde, AA; Willems, AR, 2011) |
| "A 37-year-old man with symptomatic acute atrial fibrillation and a low-voltage electrocardiogram was treated with flecainide intravenously." | 3.73 | [Life-threatening ventricular tachycardia during flecainide treatment for symptomatic atrial fibrillation in a patient with a structural cardiac disorder]. ( Rienstra, M; van Gelder, IC; van Veldhuisen, DJ; Wiesfeld, AC, 2006) |
| "Using tissue Doppler echocardiography, we studied how these contractile variables change on induction of the characteristic ST-segment changes of Brugada syndrome by flecainide challenge." | 3.72 | Delay in right ventricular activation contributes to Brugada syndrome. ( de Groot, IK; Sogaard, P; Tan, HL; Tukkie, R; Vleugels, J; Wilde, AA, 2004) |
| "The flecainide test is widely used in Brugada syndrome." | 3.72 | Flecainide test in Brugada syndrome: a reproducible but risky tool. ( Ceriotti, C; Galimberti, P; Gasparini, M; Mantica, M; Napolitano, C; Priori, SG; Simonini, S, 2003) |
| "The class IC antiarrhythmic drug flecainide has been shown to be ineffective for the treatment of ventricular arrhythmias in some patients who have had a prior myocardial infarction and sometimes even provoke arrhythmias (proarrhythmic effect)." | 3.69 | Electrophysiological effects of flecainide on anisotropic conduction and reentry in infarcted canine hearts. ( Coromilas, J; Dillon, SM; Saltman, AE; Waldecker, B; Wit, AL, 1995) |
| "The Cardiac Arrhythmia Suppression Trial has shown that flecainide was associated with an increased incidence of sudden cardiac death in postinfarction patients." | 3.69 | Reentrant arrhythmias in the subacute infarction period. The proarrhythmic effect of flecainide acetate on functional reentrant circuits. ( Assadi, MA; Avitable, MJ; Caref, EB; el-Sherif, N; Isber, N; Ndrepepa, G; Patel, AI; Restivo, M; Yin, H, 1995) |
| "The Elimination of Ventricular Premature Beats with Catheter Ablation versus Optimal Antiarrhythmic Drug Treatment (ECTOPIA) trial is a randomized, multicenter, prospective clinical trial to compare the efficacy of catheter ablation versus optimal AAD treatment with sotalol or flecainide/verapamil." | 2.94 | Elimination of Benign Ventricular Premature Beats or Ventricular Tachycardia with Catheter Ablation versus Two Different Optimal Antiarrhythmic Drug Treatment Regimens (Sotalol or Verapamil/Flecainide). ( Adiyaman, A; Beukema, RJ; de Jong, JSSG; Delnoy, PPHM; Elvan, A; Haanschoten, DM; Khan, M; Otten, AM; Ramdat Misier, AR; Smit, JJJ; Szili-Torok, T; Ter Bekke, RMA; Vernooy, K, 2020) |
| "To determine whether flecainide dosed to therapeutic levels and added to β-blocker therapy is superior to β-blocker therapy alone for the prevention of exercise-induced arrhythmias in CPVT." | 2.84 | Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia: A Randomized Clinical Trial. ( Batra, AS; Carboni, MP; Cerrone, M; Chen, H; Dzurik, MV; Ely, EW; Etheridge, SP; Fairbrother, DL; Fountain, D; Kannankeril, PJ; Kanter, RJ; Kaufman, ES; Kertesz, NJ; Knollmann, BC; Moore, JP; Priori, SG; Ro, PS; Roden, DM; Saarel, EV, 2017) |
| "The test may also induce premature ventricular complexes (PVCs) in individuals without Brugada pattern, the clinical relevance of which is little known." | 2.82 | Malignant Purkinje ectopy induced by sodium channel blockers. ( Bernus, O; Cheniti, G; Combes, N; Derval, N; Duchateau, J; Escande, W; Gandjbakhch, E; Gourraud, JB; Haissaguerre, M; Hermida, JS; Hocini, M; Jaïs, P; Krisai, P; Lavergne, T; Martins, R; Maury, P; Merino, JL; Nademanee, K; Pambrun, T; Pasquié, JL; Postema, PG; Probst, V; Sacher, F; Surget, E; Vigmond, E, 2022) |
| "This multicenter study suggests that oral flecainide therapy is an effective and safe means of suppressing VAs in patients with ATS with KCNJ2 mutations, though the U-wave amplitude remained unchanged by flecainide." | 2.80 | Efficacy and safety of flecainide for ventricular arrhythmias in patients with Andersen-Tawil syndrome with KCNJ2 mutations. ( Aiba, T; Anzai, T; Hayashi, H; Horie, M; Ishibashi, K; Ishihara, M; Kamakura, S; Kimura, H; Kusano, K; Miyamoto, K; Miyamoto, Y; Nakajima, I; Noda, T; Ogawa, H; Ohno, S; Okamura, H; Shimizu, W; Tanioka, Y; Tsuboi, I; Tsuchiya, T; Yasuda, S; Yasuoka, C; Yoshida, Y, 2015) |
| "Flecainide was reported to reduce exercise-induced ventricular arrhythmias (EIVA) in patients with ryanodine receptor-associated CPVT." | 2.78 | Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia. ( Blich, M; Boulos, M; Gepstein, L; Khoury, A; Lorber, A; Marai, I; Suleiman, M, 2013) |
| " Despite careful precautions, serious proarrhythmias, the major limiting side effect of dofetilide, still occurred during long-term follow-up." | 2.73 | Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function. ( Bauman, JL; Kehoe, RF; Leal, S; Mykytsey, A; Razminia, M; Saleem, M; Wang, T; Zheutlin, T, 2007) |
| "Amiodarone has a more favourable therapeutic profile than flecainide and propafenone in these patients, having less tendency to worsen heart failure." | 2.67 | A multicentre, randomized trial on the benefit/risk profile of amiodarone, flecainide and propafenone in patients with cardiac disease and complex ventricular arrhythmias. Antiarrhythmic Drug Evaluation Group (A.D.E.G.). ( , 1992) |
| "Flecainide did not increase the risk of all side effects (RR = 0." | 2.61 | Safety and efficacy of flecainide for patients with catecholaminergic polymorphic ventricular tachycardia: A systematic review and meta-analysis. ( Li, J; Wang, G; Wang, Y; Zhao, N; Zhong, S, 2019) |
| "Flecainide has improved CPVT outcomes and will likely have broader clinical indications in the near future." | 2.55 | Catecholaminergic polymorphic ventricular tachycardia: a model for genotype-specific therapy. ( Roston, TM; Sanatani, S; Van Petegem, F, 2017) |
| "Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inheritable cardiac disorder associated with exercise- and stress-induced sudden death in young individuals." | 2.53 | Clinical Challenges in Catecholaminergic Polymorphic Ventricular Tachycardia. ( Imberti, JF; Mazzanti, A; Priori, SG; Underwood, K, 2016) |
| "Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmogenic disease that can cause sudden cardiac death due to ventricular fibrillation (VF)." | 2.47 | Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: a case report and review of the current literature. ( Bittner, A; Dechering, DG; Eckardt, L; Köbe, J; Kotthoff, S; Mönnig, G; Muszynski, A; Pott, C; Reinke, F; Schulze-Bahr, E; Wasmer, K; Zellerhoff, S, 2011) |
| "Long QT syndrome was identified postnatally on the electrocardiogram, and was confirmed by genetic testing which showed a mutation in the KCNH2 gene (p." | 2.45 | Fetal ventricular tachycardia secondary to long QT syndrome treated with maternal intravenous magnesium: case report and review of the literature. ( Gill, H; Maxwell, D; Rosenthal, E; Simpson, JM, 2009) |
| "Flecainide is a Class IC antiarrhythmic agent whose primary electrophysiologic effect is a slowing of conduction in a wide range of cardiac tissues." | 2.39 | Flecainide. ( Falk, RH; Fogel, RI, 1994) |
| "Patients with unexplained ventricular arrhythmias (UVA) were identified as those with no structural heart disease on echocardiogram, no obstructive coronary disease, and no clear diagnostic features on ECG." | 1.91 | Diagnostic evaluation of unexplained ventricular tachyarrhythmias in younger adults. ( Kistler, P; Ling, LH; Mariani, J; Patel, H; Prabhu, S; Shirwaiker, A; Sugamar, H; Voskoboinik, A; William, J; Xiao, X, 2023) |
| "Polymorphic ventricular tachycardia (PMVT) is a rare genetic disease associated with structurally normal hearts which in 8% of cases can lead to sudden cardiac death, typically exercise-induced." | 1.91 | Personalized medicine in the dish to prevent calcium leak associated with short-coupled polymorphic ventricular tachycardia in patient-derived cardiomyocytes. ( Charrabi, A; Chen, S; Cheung, JW; Colombani, S; Evans, T; Jaffré, F; Lacampagne, A; Lerman, BB; Marks, AR; Meli, AC; Pasquié, JL; Reiken, S; Sittenfeld, LR; Sleiman, Y, 2023) |
| "Flecainide is a class 1c anti-arrhythmic drug that has demonstrated therapeutic efficacy in treating CPVT." | 1.91 | Insights on the mechanism of flecainide in catecholaminergic polymorphic ventricular tachycardia. ( Davidson, R; Medeiros, M, 2023) |
| "This study suggests that flecainide and beta-blockers association is complementary to implantable cardioverter-defibrillator and catheter ablation and is safe for treating persistent symptomatic VA in patients with ARVC." | 1.72 | Safety and efficacy of flecainide associated with beta-blockers in arrhythmogenic right ventricular cardiomyopathy. ( Badenco, N; Duthoit, G; Frank, R; Gandjbakhch, E; Hidden-Lucet, F; Himbert, C; Laredo, M; Maupain, C; Rolland, T; Waintraub, X, 2022) |
| "A novel familial arrhythmia syndrome, cardiac ryanodine receptor (RyR2) calcium release deficiency syndrome (CRDS), has recently been described." | 1.72 | Provocation Testing and Therapeutic Response in a Newly Described Channelopathy: RyR2 Calcium Release Deficiency Syndrome. ( Chen, SRW; Dreau, HMP; Ginks, MR; Guo, W; Li, Y; McGuire, K; Ormerod, JOM; Ormondroyd, E; Rajappan, K; Sarton, CNS; Taylor, J; Taylor, JC; Wang, R; Watkins, H; Wei, J, 2022) |
| " A medication episode was defined as a timeframe in which the highest dosage at a fixed level of a single drug was used in a patient." | 1.62 | The Efficacy of Anti-Arrhythmic Drugs in Children With Idiopathic Frequent Symptomatic or Asymptomatic Premature Ventricular Complexes With or Without Asymptomatic Ventricular Tachycardia: a Retrospective Multi-Center Study. ( Bertels, RA; Blom, NA; Filippini, LH; Kammeraad, JAE; Knobbe, I; Kuipers, IM; Zeelenberg, AM, 2021) |
| "Flecainide was added to the treatment regime." | 1.48 | Can flecainide totally eliminate bidirectional ventricular tachycardia in pediatric patients with Andersen-Tawil syndrome? ( Ergül, Y; Onan, SH; Özgür, S; Tuzcu, V, 2018) |
| "Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a potentially lethal hereditary disease characterized by complex ventricular arrhythmias provoked by exercise or emotional stress and by a high mortality rate in young individuals." | 1.48 | Efficacy of ivabradine to control ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia. ( Klug, D; Vaksmann, G, 2018) |
| "Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited disease characterized by polymorphic or bidirectional ventricular arrhythmias (VA) triggered by physical or emotional stress in young people with a structurally normal heart." | 1.48 | Flecainide Reduces Ventricular Arrhythmias in Patients With Genotype RyR2-positive Catecholaminergic Polymorphic Ventricular Tachycardia. ( Álvarez Acosta, L; Brugada Terradellas, J; Brugada Terradellas, R; Caballero Dorta, E; Campuzano Larrea, O; Groba Marco, MDV; Hernández Afonso, JS; Pérez, G; Wangüemert Pérez, F, 2018) |
| "Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmia syndrome characterized by fatal ventricular arrhythmias in structurally normal hearts during β-adrenergic stimulation." | 1.43 | In silico prediction of drug therapy in catecholaminergic polymorphic ventricular tachycardia. ( Clancy, CE; Grandi, E; Jeng, MT; Miyake, CY; Moreno, JD; Noskov, SY; Vaughn-Behrens, SB; Wehrens, XH; Yang, PC, 2016) |
| "Catecholaminergic polymorphic ventricular tachycardia was diagnosed by electrocardiogram at cardiac arrest (n=2), or provocation test, either by catecholamine infusion test (n=6) or exercise test (n=2)." | 1.43 | Clinical and genetic profile of catecholaminergic polymorphic ventricular tachycardia in Hong Kong Chinese children. ( Chung, BH; Liu, AP; Lun, KS; Yu, TC; Yung, TC, 2016) |
| "Flecainide testing was performed at each follow-up visits ≤6 months." | 1.42 | Brugada Syndrome Phenotype Elimination by Epicardial Substrate Ablation. ( Berruezo, A; Brugada, J; Ciconte, G; Giannelli, L; Manguso, F; Pappone, C; Santinelli, V; Vicedomini, G, 2015) |
| "Unexplained cardiac arrest (UCA) can be caused by low-penetrance genetic disorders." | 1.42 | Diagnostic Approach to Unexplained Cardiac Arrest (from the FIVI-Gen Study). ( Álvarez, M; Cózar, R; Domingo, D; Fernández Pastor, J; Gimeno, JR; Grima, EZ; Heras, RP; Jiménez-Jáimez, J; Mazuelos, F; Monserrat, L; Moriña, P; Ortiz-Genga, M; Peinado, R; Sánchez Muñoz, JJ; Segura, F; Tercedor, L, 2015) |
| "The diagnosis of ventricular tachycardia was made early in her pregnancy course but the patient had symptoms three months earlier." | 1.42 | Right ventricular outflow tract tachycardia worsened during pregnancy. ( Amoussou, M; Kambiré, Y; Konaté, L; Millogo, GR; Nebié, LV; Niakara, A; Sib, E, 2015) |
| "Flecainide was initiated because of significant ventricular arrhythmias (n = 8), syncope (n = 3), or cardiac arrest (n = 1)." | 1.39 | Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia. ( Adler, A; Bhuiyan, ZA; Bikker, H; Horie, M; Kannankeril, PJ; Knollmann, BC; Minamino, T; Roses-Noguer, F; Rosso, R; Sumitomo, N; Till, J; van der Werf, C; Veltmann, C; Viskin, S; Watanabe, H; Wilde, AA, 2013) |
| "Catecholaminergic polymorphic ventricular tachycardia was diagnosed with the aid of an implantable loop recorder." | 1.39 | A de novo novel cardiac ryanodine mutation (Ser4155Tyr) associated with catecholaminergic polymorphic ventricular tachycardia. ( Anastasakis, A; Kotsaka, X; Luria, D; Mantziari, L; Paraskevaidis, S; Styliadis, IH; Vassilikos, V, 2013) |
| "Control animals developed premature ventricular complexes (PVCs) followed by ventricular tachycardia, which terminated in VF in 5 of the 8 dogs." | 1.39 | HBI-3000 prevents secondary sudden cardiac death. ( Lee, JY; Lucchesi, BR, 2013) |
| "Flecainide is a class 1C antiarrhythmic drug especially used for the management of supraventricular arrhythmia." | 1.39 | Arrhythmogenic effect of flecainide toxicity. ( Bonnefoy, E; Courand, PY; Kirkorian, G; Mullier, A; Ranc, S; Sibellas, F, 2013) |
| "Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited condition associated with ventricular tachycardia (VT) triggered by exercise or sympathetic stress." | 1.38 | Flecainide suppresses defibrillator-induced storming in catecholaminergic polymorphic ventricular tachycardia. ( Choi, JJ; Hong, RA; Jittirat, A; Rivera, KK, 2012) |
| "Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an arrhythmogenic disease for which electrophysiological studies (EPS) have shown to be of limited value." | 1.37 | Postpacing abnormal repolarization in catecholaminergic polymorphic ventricular tachycardia associated with a mutation in the cardiac ryanodine receptor gene. ( Antzelevitch, C; Arad, M; Belhassen, B; Bhuiyan, ZA; El-Ani, D; Eldar, M; Fogelman, R; Glikson, M; Luria, D; Mannens, MM; Nof, E; Rosso, R; Viskin, S; Wilde, AA, 2011) |
| "Propafenone was stereoselective, with R-propafenone suppressing waves more potently than S-propafenone (IC(50): R-propafenone 2 ± 0." | 1.37 | Efficacy and potency of class I antiarrhythmic drugs for suppression of Ca2+ waves in permeabilized myocytes lacking calsequestrin. ( Galimberti, ES; Knollmann, BC, 2011) |
| "Catecholaminergic polymorphic ventricular tachycardia (CPVT) is caused by mutations in the cardiac ryanodine receptor (RyR2) or calsequestrin (Casq2) and can be difficult to treat." | 1.37 | Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia. ( Faggioni, M; Hasdemir, C; Hwang, HS; Knollmann, BC; Laver, D; Mehra, D; Turhan, K; Yin, H, 2011) |
| "Palpitations in pregnancy are not an uncommon complaint." | 1.35 | Paroxysmal bidirectional ventricular tachycardia with tachycardiomyopathy in a pregnant woman. ( Cobbe, SM; McGavigan, AD; Walker, NL, 2009) |
| "Bidirectional ventricular tachycardia (BVT), although a rare arrhythmia in the general population, is frequently observed in patients with Andersen-Tawil syndrome and long QT interval." | 1.35 | Flecainide suppresses bidirectional ventricular tachycardia and reverses tachycardia-induced cardiomyopathy in Andersen-Tawil syndrome. ( Gonzalez, MD; Kalaizich, L; Pellizzón, OA; Ptácek, LJ; Tristani-Firouzi, M, 2008) |
| "We discovered that flecainide prevents arrhythmias in a mouse model of CPVT by inhibiting cardiac ryanodine receptor-mediated Ca(2+) release and thereby directly targeting the underlying molecular defect." | 1.35 | Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. ( Chopra, N; Davies, SS; Duff, HJ; Hwang, HS; Knollmann, BC; Laver, D; Roach, DE; Roden, DM; Watanabe, H; Wilde, AA, 2009) |
| "He had incomplete left bundle branch block with left-axis deviation." | 1.31 | His-Purkinje system reentry as a proarrhythmic effect of flecainide. ( Barra, N; Cellarier, G; Chalvidan, T; Colin, R; Deharo, JC; Djiane, P; Peyre, JP; Savon, N, 2000) |
| "Propranolol or flecainide was added to the treatment protocol for two patients who did not respond to verapamil alone." | 1.31 | Idiopathic sustained left ventricular tachycardia in pediatric patients. ( Iwamoto, M; Kobayashi, H; Niimura, I; Nishizawa, T; Sakon, T; Shibata, T; Takigiku, K; Yasui, K; Yokoyama, U, 2001) |
| "Verapamil was infused into the superior vena cava over 15-20 min." | 1.30 | Effects of verapamil in ventricular tachycardias. An experimental and clinical study. ( Casanova, JM; De Micheli, A; Iturralde, P; Medrano, GA, 1997) |
| "Flecainide acetate is a potent class Ic anti-arrhythmic drug with major sodium channel blocking actions." | 1.30 | Survival in a case of life-threatening flecainide overdose. ( Bourke, JP; Gascoigne, AD; Hanley, NA, 1998) |
| "No evidence of ischemic heart disease was detected." | 1.30 | Class IC antiarrhythmic drugs, flecainide and pilsicainide, produce ST segment elevation simulating inferior myocardial ischemia. ( Ito, H; Nakamura, W; Segawa, K; Tanaka, S; Yoshimoto, N, 1998) |
| "Patient 1 had frequent episodes of paroxysmal atrial fibrillation resistant to Class IA drugs." | 1.30 | ST segment elevation in the right precordial leads induced with class IC antiarrhythmic drugs: insight into the mechanism of Brugada syndrome. ( Fujiki, A; Hayashi, H; Inoue, H; Mizumaki, K; Nagasawa, H; Usui, M, 1999) |
| "Following flecainide administration, a ventricular tachycardia with close resemblance of the ECG morphology to sinus rhythm was induced." | 1.29 | Pleomorphic ventricular tachycardia with antegrade His-bundle activation: elucidation by multiple His-bundle recordings. ( Lee, KL; Tai, YT, 1994) |
| "The diagnosis of ventricular tachycardia is difficult, often requiring endocavitary investigation to obtain proof." | 1.29 | [Tachycardia with wide QRS. Limitations of electrocardiographic criteria in patients treated with anti-arrhythmia agents]. ( Dupuis, JM; Le Davay, M; Merheb, M; Tadeï, A; Tran, P; Victor, J, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 26 (19.40) | 18.2507 |
| 2000's | 17 (12.69) | 29.6817 |
| 2010's | 62 (46.27) | 24.3611 |
| 2020's | 29 (21.64) | 2.80 |
| Authors | Studies |
|---|---|
| Rolland, T | 1 |
| Badenco, N | 1 |
| Maupain, C | 1 |
| Duthoit, G | 1 |
| Waintraub, X | 1 |
| Laredo, M | 1 |
| Himbert, C | 1 |
| Frank, R | 1 |
| Hidden-Lucet, F | 1 |
| Gandjbakhch, E | 2 |
| Liu, JS | 1 |
| Fan, EH | 1 |
| Salvage, SC | 2 |
| Habib, ZF | 1 |
| Matthews, HR | 1 |
| Jackson, AP | 1 |
| Huang, CL | 3 |
| Bannister, ML | 3 |
| MacLeod, KT | 3 |
| George, CH | 3 |
| Ormerod, JOM | 1 |
| Ormondroyd, E | 1 |
| Li, Y | 1 |
| Taylor, J | 1 |
| Wei, J | 1 |
| Guo, W | 1 |
| Wang, R | 1 |
| Sarton, CNS | 1 |
| McGuire, K | 1 |
| Dreau, HMP | 1 |
| Taylor, JC | 1 |
| Ginks, MR | 1 |
| Rajappan, K | 1 |
| Chen, SRW | 1 |
| Watkins, H | 1 |
| Ünal Yüksekgönül, A | 1 |
| Azak, E | 1 |
| Akalın, A | 1 |
| Ertuğrul, İ | 1 |
| Kılıç, E | 1 |
| Utine, GE | 1 |
| Karagöz, T | 1 |
| Fraser, JA | 1 |
| Dulhunty, AF | 1 |
| Escande, W | 1 |
| Gourraud, JB | 1 |
| Haissaguerre, M | 2 |
| Lavergne, T | 1 |
| Martins, R | 1 |
| Cheniti, G | 1 |
| Krisai, P | 1 |
| Hermida, JS | 1 |
| Maury, P | 1 |
| Merino, JL | 1 |
| Pasquié, JL | 2 |
| Combes, N | 1 |
| Surget, E | 1 |
| Duchateau, J | 1 |
| Pambrun, T | 1 |
| Derval, N | 1 |
| Hocini, M | 1 |
| Jaïs, P | 1 |
| Postema, PG | 1 |
| Nademanee, K | 1 |
| Vigmond, E | 1 |
| Bernus, O | 1 |
| Sacher, F | 2 |
| Probst, V | 1 |
| Ryan, K | 1 |
| Benz, P | 1 |
| Zosel, A | 1 |
| Farkas, A | 1 |
| Theobald, J | 1 |
| William, J | 1 |
| Xiao, X | 1 |
| Shirwaiker, A | 1 |
| Patel, H | 1 |
| Prabhu, S | 1 |
| Ling, LH | 1 |
| Sugamar, H | 1 |
| Mariani, J | 1 |
| Kistler, P | 1 |
| Voskoboinik, A | 1 |
| Kiani, S | 1 |
| Sayegh, MN | 1 |
| Ibrahim, R | 1 |
| Bhatia, NK | 1 |
| Merchant, FM | 1 |
| Shah, AD | 1 |
| Westerman, SB | 1 |
| De Lurgio, DB | 1 |
| Patel, AM | 1 |
| Thompkins, CM | 1 |
| Leon, AR | 1 |
| Lloyd, MS | 1 |
| El-Chami, MF | 1 |
| Basza, M | 1 |
| Maciejewski, C | 1 |
| Bojanowicz, W | 1 |
| Balsam, P | 1 |
| Grabowski, M | 1 |
| Mitkowski, P | 1 |
| Kempa, M | 1 |
| Kowalski, O | 1 |
| Kalarus, Z | 1 |
| Jaguszewski, M | 1 |
| Lubiński, A | 1 |
| Daniłowicz-Szymanowicz, L | 1 |
| Szumowski, Ł | 1 |
| Sterliński, M | 1 |
| Kołtowski, Ł | 1 |
| Przybylski, R | 1 |
| Abrams, DJ | 1 |
| Ebrahim, MA | 1 |
| Alkhabbaz, AA | 1 |
| Albash, B | 1 |
| AlSayegh, AH | 1 |
| Webster, G | 1 |
| Kallas, D | 1 |
| Roberts, JD | 1 |
| Sanatani, S | 4 |
| Roston, TM | 4 |
| Sleiman, Y | 1 |
| Reiken, S | 1 |
| Charrabi, A | 1 |
| Jaffré, F | 1 |
| Sittenfeld, LR | 1 |
| Colombani, S | 1 |
| Lerman, BB | 1 |
| Chen, S | 1 |
| Marks, AR | 1 |
| Cheung, JW | 1 |
| Evans, T | 1 |
| Lacampagne, A | 1 |
| Meli, AC | 1 |
| Davidson, R | 1 |
| Medeiros, M | 1 |
| Wang, G | 1 |
| Zhao, N | 1 |
| Zhong, S | 1 |
| Wang, Y | 1 |
| Li, J | 1 |
| Nozaki, Y | 1 |
| Kato, Y | 1 |
| Uike, K | 1 |
| Yamamura, K | 1 |
| Kikuchi, M | 1 |
| Yasuda, M | 1 |
| Ohno, S | 2 |
| Horie, M | 3 |
| Murayama, T | 1 |
| Kurebayashi, N | 1 |
| Horigome, H | 1 |
| Bensussan, H | 1 |
| Mhamdi, K | 1 |
| Kohli, U | 2 |
| Aziz, Z | 2 |
| Beaser, AD | 2 |
| Nayak, HM | 2 |
| Newson, JM | 1 |
| Santos, CD | 1 |
| Walters, BL | 1 |
| Todd, BR | 1 |
| Wagner, J | 1 |
| Fitzpatrick, J | 1 |
| Goldschlager, N | 1 |
| Haanschoten, DM | 1 |
| Vernooy, K | 1 |
| Beukema, RJ | 1 |
| Szili-Torok, T | 1 |
| Ter Bekke, RMA | 1 |
| Khan, M | 1 |
| de Jong, JSSG | 1 |
| Otten, AM | 1 |
| Adiyaman, A | 1 |
| Smit, JJJ | 1 |
| Delnoy, PPHM | 1 |
| Ramdat Misier, AR | 1 |
| Elvan, A | 1 |
| Rujirachun, P | 1 |
| Junyavoraluk, A | 1 |
| Pithukpakorn, M | 1 |
| Suktitipat, B | 1 |
| Winijkul, A | 1 |
| Schumer, A | 1 |
| Contag, S | 1 |
| Donthi, N | 1 |
| Chandrabhatla, T | 1 |
| Genovese, L | 1 |
| deFilippi, C | 1 |
| Bertels, RA | 1 |
| Kammeraad, JAE | 1 |
| Zeelenberg, AM | 1 |
| Filippini, LH | 1 |
| Knobbe, I | 1 |
| Kuipers, IM | 1 |
| Blom, NA | 2 |
| Benitah, JP | 1 |
| Gómez, AM | 1 |
| Tanaka, TD | 1 |
| Suzuki, T | 1 |
| Marcus, FI | 1 |
| Kannankeril, PJ | 3 |
| Moore, JP | 1 |
| Cerrone, M | 1 |
| Priori, SG | 5 |
| Kertesz, NJ | 1 |
| Ro, PS | 1 |
| Batra, AS | 1 |
| Kaufman, ES | 1 |
| Fairbrother, DL | 1 |
| Saarel, EV | 1 |
| Etheridge, SP | 1 |
| Kanter, RJ | 1 |
| Carboni, MP | 1 |
| Dzurik, MV | 1 |
| Fountain, D | 1 |
| Chen, H | 1 |
| Ely, EW | 1 |
| Roden, DM | 2 |
| Knollmann, BC | 7 |
| Poli, S | 1 |
| Toniolo, M | 1 |
| Maiani, M | 1 |
| Zanuttini, D | 1 |
| Rebellato, L | 1 |
| Vendramin, I | 1 |
| Dametto, E | 1 |
| Bernardi, G | 1 |
| Bassi, F | 1 |
| Napolitano, C | 5 |
| Livi, U | 1 |
| Proclemer, A | 1 |
| Aksu, T | 1 |
| Güler, TE | 1 |
| Özcan, KS | 1 |
| Bozyel, S | 1 |
| Yalın, K | 1 |
| Wangüemert Pérez, F | 1 |
| Hernández Afonso, JS | 1 |
| Groba Marco, MDV | 1 |
| Caballero Dorta, E | 1 |
| Álvarez Acosta, L | 1 |
| Campuzano Larrea, O | 1 |
| Pérez, G | 1 |
| Brugada Terradellas, J | 1 |
| Brugada Terradellas, R | 1 |
| Watts, TE | 1 |
| McElderry, HT | 1 |
| Kay, GN | 1 |
| Evans, WN | 1 |
| Acherman, RJ | 1 |
| Law, IH | 1 |
| Von Bergen, NH | 1 |
| Samson, RA | 1 |
| Restrepo, H | 1 |
| Vaksmann, G | 1 |
| Klug, D | 1 |
| Friberg, L | 1 |
| Pflaumer, A | 1 |
| Davis, AM | 1 |
| Ergül, Y | 1 |
| Özgür, S | 1 |
| Onan, SH | 1 |
| Tuzcu, V | 1 |
| Banavalikar, B | 1 |
| Shenthar, J | 1 |
| Padmanabhan, D | 1 |
| Bucklew, EA | 1 |
| Reis, SE | 1 |
| Kancharla, K | 1 |
| Wilgenhof, A | 1 |
| Michiels, V | 1 |
| Cosyns, B | 1 |
| Courand, PY | 1 |
| Sibellas, F | 1 |
| Ranc, S | 1 |
| Mullier, A | 1 |
| Kirkorian, G | 1 |
| Bonnefoy, E | 1 |
| Lee, JY | 1 |
| Lucchesi, BR | 1 |
| Khoury, A | 1 |
| Marai, I | 1 |
| Suleiman, M | 1 |
| Blich, M | 1 |
| Lorber, A | 1 |
| Gepstein, L | 1 |
| Boulos, M | 1 |
| Gopinathannair, R | 1 |
| Ermakov, S | 1 |
| Hoffmayer, KS | 1 |
| Gerstenfeld, EP | 1 |
| Scheinman, MM | 1 |
| Mantziari, L | 1 |
| Vassilikos, V | 1 |
| Anastasakis, A | 1 |
| Kotsaka, X | 1 |
| Paraskevaidis, S | 1 |
| Styliadis, IH | 1 |
| Luria, D | 2 |
| Osadchii, OE | 2 |
| Massin, M | 1 |
| Ould, AF | 1 |
| Jacquemart, C | 1 |
| Damry, N | 1 |
| Wangüemert-Pérez, F | 1 |
| Ruiz-Hernández, PM | 1 |
| Campuzano, O | 1 |
| Caballero-Dorta, E | 1 |
| Bosch, C | 1 |
| Brugada, J | 2 |
| Brugada, R | 1 |
| Kwan, D | 1 |
| Vohra, R | 1 |
| Dyer, JE | 1 |
| Dornhoffer, P | 1 |
| Miyamoto, K | 1 |
| Aiba, T | 1 |
| Kimura, H | 1 |
| Hayashi, H | 3 |
| Yasuoka, C | 1 |
| Tanioka, Y | 1 |
| Tsuchiya, T | 1 |
| Yoshida, Y | 1 |
| Tsuboi, I | 1 |
| Nakajima, I | 1 |
| Ishibashi, K | 1 |
| Okamura, H | 1 |
| Noda, T | 1 |
| Ishihara, M | 1 |
| Anzai, T | 1 |
| Yasuda, S | 1 |
| Miyamoto, Y | 1 |
| Kamakura, S | 1 |
| Kusano, K | 1 |
| Ogawa, H | 1 |
| Shimizu, W | 2 |
| Thomas, NL | 2 |
| Sikkel, MB | 2 |
| Mukherjee, S | 2 |
| Maxwell, C | 2 |
| Williams, AJ | 2 |
| Smith, GL | 1 |
| MacQuaide, N | 1 |
| Tsai, WC | 1 |
| Lu, YY | 1 |
| Chen, YC | 1 |
| Chang, CJ | 1 |
| Kao, YH | 1 |
| Lin, YK | 1 |
| Chen, YH | 1 |
| Chen, SA | 1 |
| Yang, LY | 1 |
| Chen, YJ | 1 |
| Kambiré, Y | 1 |
| Konaté, L | 1 |
| Millogo, GR | 1 |
| Sib, E | 1 |
| Amoussou, M | 1 |
| Nebié, LV | 1 |
| Niakara, A | 1 |
| Jiménez-Jáimez, J | 1 |
| Peinado, R | 1 |
| Grima, EZ | 1 |
| Segura, F | 1 |
| Moriña, P | 1 |
| Sánchez Muñoz, JJ | 1 |
| Mazuelos, F | 1 |
| Cózar, R | 1 |
| Gimeno, JR | 1 |
| Heras, RP | 1 |
| Monserrat, L | 1 |
| Domingo, D | 1 |
| Ortiz-Genga, M | 1 |
| Fernández Pastor, J | 1 |
| Álvarez, M | 1 |
| Tercedor, L | 1 |
| Pappone, C | 1 |
| Berruezo, A | 1 |
| Vicedomini, G | 1 |
| Manguso, F | 1 |
| Ciconte, G | 1 |
| Giannelli, L | 1 |
| Santinelli, V | 1 |
| Padfield, GJ | 1 |
| AlAhmari, L | 1 |
| Lieve, KV | 1 |
| AlAhmari, T | 1 |
| Wilde, AA | 8 |
| Krahn, AD | 2 |
| Yang, PC | 1 |
| Moreno, JD | 1 |
| Miyake, CY | 1 |
| Vaughn-Behrens, SB | 1 |
| Jeng, MT | 1 |
| Grandi, E | 1 |
| Wehrens, XH | 1 |
| Noskov, SY | 1 |
| Clancy, CE | 1 |
| Imberti, JF | 1 |
| Underwood, K | 1 |
| Mazzanti, A | 1 |
| Yu, TC | 1 |
| Liu, AP | 1 |
| Lun, KS | 1 |
| Chung, BH | 1 |
| Yung, TC | 1 |
| Valentino, MA | 1 |
| Panakos, A | 1 |
| Ragupathi, L | 1 |
| Williams, J | 1 |
| Pavri, BB | 1 |
| Preininger, MK | 1 |
| Jha, R | 1 |
| Maxwell, JT | 1 |
| Wu, Q | 1 |
| Singh, M | 1 |
| Wang, B | 1 |
| Dalal, A | 1 |
| Mceachin, ZT | 1 |
| Rossoll, W | 1 |
| Hales, CM | 1 |
| Fischbach, PS | 1 |
| Wagner, MB | 1 |
| Xu, C | 1 |
| Bacic, D | 1 |
| Carneiro, JS | 1 |
| Bento, AA | 1 |
| Nearing, BD | 1 |
| Rajamani, S | 1 |
| Belardinelli, L | 1 |
| Verrier, RL | 1 |
| Van Petegem, F | 1 |
| Cunningham, TC | 1 |
| Yavari, A | 1 |
| Fryer, J | 1 |
| Walker, DM | 1 |
| Watanabe, H | 4 |
| Chopra, N | 1 |
| Laver, D | 2 |
| Hwang, HS | 2 |
| Davies, SS | 1 |
| Roach, DE | 1 |
| Duff, HJ | 1 |
| Walker, NL | 1 |
| Cobbe, SM | 1 |
| McGavigan, AD | 1 |
| Simpson, JM | 1 |
| Maxwell, D | 1 |
| Rosenthal, E | 1 |
| Gill, H | 1 |
| Letsas, KP | 1 |
| Weber, R | 1 |
| Astheimer, K | 1 |
| Kalusche, D | 1 |
| Arentz, T | 1 |
| Lu, HR | 1 |
| Rohrbacher, J | 1 |
| Vlaminckx, E | 1 |
| Van Ammel, K | 1 |
| Yan, GX | 1 |
| Gallacher, DJ | 1 |
| Biernacka, EK | 1 |
| Hoffman, P | 1 |
| van der Werf, C | 3 |
| Barajas-Martinez, H | 1 |
| Hu, D | 1 |
| Ontiveros, G | 1 |
| Caceres, G | 1 |
| Desai, M | 1 |
| Burashnikov, E | 1 |
| Scaglione, J | 1 |
| Antzelevitch, C | 2 |
| Soltysinska, E | 1 |
| Olesen, SP | 1 |
| Hasdemir, C | 1 |
| Mehra, D | 1 |
| Turhan, K | 1 |
| Faggioni, M | 1 |
| Yin, H | 2 |
| Pott, C | 1 |
| Dechering, DG | 1 |
| Reinke, F | 1 |
| Muszynski, A | 1 |
| Zellerhoff, S | 1 |
| Bittner, A | 1 |
| Köbe, J | 1 |
| Wasmer, K | 1 |
| Schulze-Bahr, E | 1 |
| Mönnig, G | 1 |
| Kotthoff, S | 1 |
| Eckardt, L | 1 |
| Martin, CA | 1 |
| Guzadhur, L | 1 |
| Grace, AA | 1 |
| Lei, M | 1 |
| Viskin, S | 3 |
| Leenhardt, A | 2 |
| Sumitomo, N | 2 |
| Fish, FA | 1 |
| Bhuiyan, ZA | 3 |
| Willems, AR | 1 |
| van der Veen, MJ | 1 |
| Laborderie, J | 1 |
| Liu, N | 2 |
| Denegri, M | 1 |
| Ruan, Y | 1 |
| Avelino-Cruz, JE | 1 |
| Perissi, A | 1 |
| Negri, S | 1 |
| Coetzee, WA | 1 |
| Boyden, PA | 1 |
| Nof, E | 1 |
| Belhassen, B | 1 |
| Arad, M | 1 |
| Rosso, R | 2 |
| Fogelman, R | 1 |
| El-Ani, D | 1 |
| Mannens, MM | 1 |
| Eldar, M | 1 |
| Glikson, M | 1 |
| Galimberti, ES | 1 |
| Steele, DS | 1 |
| Hong, RA | 1 |
| Rivera, KK | 1 |
| Jittirat, A | 1 |
| Choi, JJ | 1 |
| Venetucci, LA | 1 |
| Denjoy, I | 1 |
| Guicheney, P | 1 |
| Roses-Noguer, F | 1 |
| Adler, A | 1 |
| Veltmann, C | 1 |
| Bikker, H | 1 |
| Minamino, T | 1 |
| Till, J | 1 |
| Apostolakis, S | 1 |
| Oeff, M | 1 |
| Tebbe, U | 1 |
| Fabritz, L | 1 |
| Breithardt, G | 1 |
| Kirchhof, P | 1 |
| D'Souza, D | 1 |
| MacKenzie, WE | 1 |
| Martin, WL | 1 |
| Gasparini, M | 1 |
| Mantica, M | 1 |
| Galimberti, P | 1 |
| Ceriotti, C | 1 |
| Simonini, S | 1 |
| Ackland, F | 1 |
| Singh, R | 1 |
| Thayyil, S | 1 |
| Tukkie, R | 1 |
| Sogaard, P | 1 |
| Vleugels, J | 1 |
| de Groot, IK | 1 |
| Tan, HL | 1 |
| Kanemoto, M | 1 |
| Shimizu, A | 1 |
| Yamagata, T | 1 |
| Esato, M | 1 |
| Ueyama, T | 1 |
| Yoshiga, Y | 1 |
| Kakugawa, H | 1 |
| Kametani, R | 1 |
| Inoue, N | 1 |
| Sawa, A | 1 |
| Matsuzaki, M | 1 |
| Haghjoo, M | 1 |
| Arya, A | 1 |
| Emkanjoo, Z | 1 |
| Sadr-Ameli, MA | 1 |
| Rienstra, M | 1 |
| Wiesfeld, AC | 1 |
| van Veldhuisen, DJ | 1 |
| van Gelder, IC | 1 |
| Bökenkamp, R | 1 |
| Schalij, MJ | 1 |
| Mykytsey, A | 1 |
| Bauman, JL | 1 |
| Razminia, M | 1 |
| Zheutlin, T | 1 |
| Wang, T | 1 |
| Saleem, M | 1 |
| Leal, S | 1 |
| Kehoe, RF | 1 |
| Pellizzón, OA | 1 |
| Kalaizich, L | 1 |
| Ptácek, LJ | 1 |
| Tristani-Firouzi, M | 1 |
| Gonzalez, MD | 1 |
| Stramba-Badiale, M | 1 |
| Lazzarotti, M | 1 |
| Facchini, M | 1 |
| Schwartz, PJ | 1 |
| Ranger, S | 1 |
| Nattel, S | 1 |
| Jung, W | 1 |
| Mletzko, R | 1 |
| Manz, M | 1 |
| Nitsch, J | 1 |
| Lüderitz, B | 1 |
| Coromilas, J | 1 |
| Saltman, AE | 1 |
| Waldecker, B | 1 |
| Dillon, SM | 1 |
| Wit, AL | 1 |
| Salerno, DM | 1 |
| Murakami, MM | 1 |
| Johnston, RB | 1 |
| Keyler, DE | 1 |
| Pentel, PR | 1 |
| Restivo, M | 1 |
| Caref, EB | 1 |
| Patel, AI | 1 |
| Ndrepepa, G | 1 |
| Avitable, MJ | 1 |
| Assadi, MA | 1 |
| Isber, N | 1 |
| el-Sherif, N | 1 |
| Falk, RH | 1 |
| Fogel, RI | 1 |
| Fenrich, AL | 1 |
| Perry, JC | 1 |
| Friedman, RA | 1 |
| Connaughton, M | 1 |
| Jenkins, BS | 1 |
| Tai, YT | 1 |
| Lee, KL | 1 |
| Le Davay, M | 1 |
| Victor, J | 1 |
| Dupuis, JM | 1 |
| Merheb, M | 1 |
| Tran, P | 1 |
| Tadeï, A | 1 |
| Said, SA | 1 |
| Somer, ST | 1 |
| Oude Luttikhuis, HA | 1 |
| Ismail, Z | 1 |
| Alwi, M | 1 |
| Lim, MK | 1 |
| Murtazam, HA | 1 |
| Jamaluddin, A | 1 |
| Gutiérrez-Larraya, F | 1 |
| Jabón, A | 1 |
| Ogawa, S | 1 |
| Mitamura, H | 1 |
| Katoh, H | 1 |
| Tisdale, JE | 1 |
| Kluger, J | 1 |
| Fisher, JR | 1 |
| Chow, MS | 1 |
| Kidwell, GA | 1 |
| Greenspon, AJ | 1 |
| Greenberg, RM | 1 |
| Volosin, KJ | 1 |
| van Hemel, NM | 1 |
| Kingma, JH | 1 |
| Defauw, JJ | 1 |
| Hoogteijling-van Dusseldorp, E | 1 |
| Kelder, JC | 1 |
| Beukema, WP | 1 |
| Vermeulen, FE | 1 |
| De Micheli, A | 1 |
| Medrano, GA | 1 |
| Iturralde, P | 1 |
| Casanova, JM | 1 |
| Hanley, NA | 1 |
| Bourke, JP | 1 |
| Gascoigne, AD | 1 |
| Nakamura, W | 1 |
| Segawa, K | 1 |
| Ito, H | 1 |
| Tanaka, S | 1 |
| Yoshimoto, N | 1 |
| Fujiki, A | 1 |
| Usui, M | 1 |
| Nagasawa, H | 1 |
| Mizumaki, K | 1 |
| Inoue, H | 1 |
| Swan, H | 1 |
| Piippo, K | 1 |
| Viitasalo, M | 1 |
| Heikkilä, P | 1 |
| Paavonen, T | 1 |
| Kainulainen, K | 1 |
| Kere, J | 1 |
| Keto, P | 1 |
| Kontula, K | 1 |
| Toivonen, L | 1 |
| Chalvidan, T | 1 |
| Cellarier, G | 1 |
| Deharo, JC | 1 |
| Colin, R | 1 |
| Savon, N | 1 |
| Barra, N | 1 |
| Peyre, JP | 1 |
| Djiane, P | 1 |
| Watanabe, T | 1 |
| Yamaki, M | 1 |
| Tachibana, H | 1 |
| Yamauchi, S | 1 |
| Kubota, I | 1 |
| Tomoike, H | 1 |
| Yasui, K | 1 |
| Shibata, T | 1 |
| Yokoyama, U | 1 |
| Nishizawa, T | 1 |
| Takigiku, K | 1 |
| Sakon, T | 1 |
| Kobayashi, H | 1 |
| Iwamoto, M | 1 |
| Niimura, I | 1 |
| Lombardi, F | 1 |
| Torzillo, D | 1 |
| Sandrone, G | 1 |
| Dalla Vecchia, L | 1 |
| Cappiello, E | 1 |
| Gill, JS | 1 |
| Mehta, D | 1 |
| Ward, DE | 1 |
| Camm, AJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective Randomized Crossover Trial of Oral Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia[NCT01117454] | 14 participants (Actual) | Interventional | 2011-12-31 | Completed | |||
| Electrical Substrate Elimination in Brugada Syndrome. Results in 135 Consecutive Patients[NCT02641431] | 135 participants (Actual) | Interventional | 2015-11-16 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Hypothesis: the addition of oral flecainide to standard therapy will reduce ventricular ectopy and/or VT on treadmill exercise treadmill testing in patients with CPVT, compared to placebo plus standard therapy. (NCT01117454)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Flecainide | 2 |
| Placebo | 9 |
22 reviews available for flecainide and Tachycardia, Ventricular
| Article | Year |
|---|---|
Ca2+-dependent modulation of voltage-gated myocyte sodium channels.
Topics: Action Potentials; Animals; Binding Sites; Calcium; Calcium Signaling; Disease Models, Animal; Fleca | 2021 |
Moving in the right direction: elucidating the mechanisms of interaction between flecainide and the cardiac ryanodine receptor.
Topics: Anti-Arrhythmia Agents; Calcium; Flecainide; Humans; Mutation; Myocytes, Cardiac; Ryanodine Receptor | 2022 |
Malignant Purkinje ectopy induced by sodium channel blockers.
Topics: Adult; Ajmaline; Catheter Ablation; Electrocardiography; Flecainide; Humans; Male; Middle Aged; Repr | 2022 |
Flecainide in clinical practice.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Child; Female; Flecainide; Humans; Pregnancy; Propafeno | 2023 |
Current management of inherited arrhythmia syndromes associated with the cardiac ryanodine receptor.
Topics: Adrenergic beta-Antagonists; Flecainide; Humans; Mutation; Nadolol; Ryanodine Receptor Calcium Relea | 2023 |
Calcium Release Deficiency Syndrome: A New Inherited Arrhythmia Syndrome.
Topics: Calcium; Electrocardiography; Flecainide; Humans; Mutation; Ryanodine Receptor Calcium Release Chann | 2023 |
Safety and efficacy of flecainide for patients with catecholaminergic polymorphic ventricular tachycardia: A systematic review and meta-analysis.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Female; Flecainide; Humans; Male; Randomized Co | 2019 |
[Flecainid intoxication: Evolution, complications and care of].
Topics: Anti-Arrhythmia Agents; Asperger Syndrome; Flecainide; Humans; Length of Stay; Male; Suicide, Attemp | 2020 |
Successful treatment of arrhythmia with β-blocker and flecainide combination in pregnant patients with Andersen-Tawil syndrome: A case report and literature review.
Topics: Adrenergic beta-Antagonists; Adult; Andersen Syndrome; Anti-Arrhythmia Agents; Female; Flecainide; H | 2021 |
Management of untreatable ventricular arrhythmias during pharmacologic challenges with sodium channel blockers for suspected Brugada syndrome.
Topics: Action Potentials; Adolescent; Adult; Aged; Aged, 80 and over; Ajmaline; Brugada Syndrome; Cardiopul | 2018 |
An Update on the Diagnosis and Management of Catecholaminergic Polymorphic Ventricular Tachycardia.
Topics: Adrenergic beta-Antagonists; Calsequestrin; Defibrillators, Implantable; Flecainide; Humans; Mutatio | 2019 |
Clinical Challenges in Catecholaminergic Polymorphic Ventricular Tachycardia.
Topics: Female; Flecainide; Humans; Male; Prevalence; Sympathectomy; Tachycardia, Ventricular | 2016 |
Flecainide Toxicity: A Case Report and Systematic Review of its Electrocardiographic Patterns and Management.
Topics: Anti-Arrhythmia Agents; Disease Management; Electrocardiography; Flecainide; Humans; Male; Middle Ag | 2017 |
Catecholaminergic polymorphic ventricular tachycardia: a model for genotype-specific therapy.
Topics: Animals; Anti-Arrhythmia Agents; Defibrillators, Implantable; Flecainide; Genetic Therapy; Genotype; | 2017 |
Advances in the diagnosis and treatment of catecholaminergic polymorphic ventricular tachycardia.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implant | 2017 |
Fetal ventricular tachycardia secondary to long QT syndrome treated with maternal intravenous magnesium: case report and review of the literature.
Topics: Adult; Anti-Arrhythmia Agents; Female; Fetal Diseases; Flecainide; Humans; Injections, Intravenous; | 2009 |
Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: a case report and review of the current literature.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Calcium Channel Blockers; Child; Death, Sudden, | 2011 |
Flecainide and antiarrhythmic effects in a mouse model of catecholaminergic polymorphic ventricular tachycardia.
Topics: Animals; Anti-Arrhythmia Agents; Catecholamines; Disease Models, Animal; Flecainide; Mice; Myocytes, | 2012 |
Catecholaminergic polymorphic ventricular tachycardia.
Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Calsequestrin; Defibrillators, Implant | 2012 |
Flecainide acetate for the treatment of atrial and ventricular arrhythmias.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Flecainide; Humans; Prac | 2013 |
Flecainide.
Topics: Atrial Fibrillation; Electrocardiography; Flecainide; Heart; Hemodynamics; Humans; Tachycardia, Vent | 1994 |
[Tachycardias: considerations in childhood in the 90s].
Topics: Adenosine; Adolescent; Adult; Amiodarone; Atrial Flutter; Child; Child, Preschool; Electrocardiograp | 1993 |
7 trials available for flecainide and Tachycardia, Ventricular
| Article | Year |
|---|---|
Elimination of Benign Ventricular Premature Beats or Ventricular Tachycardia with Catheter Ablation versus Two Different Optimal Antiarrhythmic Drug Treatment Regimens (Sotalol or Verapamil/Flecainide).
Topics: Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Catheter Ablation; Flecainide; Humans; Prospec | 2020 |
Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia: A Randomized Clinical Trial.
Topics: Adolescent; Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Cross-Over Studies; Death, Sudden, | 2017 |
Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia.
Topics: Adolescent; Anti-Arrhythmia Agents; Calsequestrin; Death, Sudden, Cardiac; DNA; Electrocardiography; | 2013 |
Efficacy and safety of flecainide for ventricular arrhythmias in patients with Andersen-Tawil syndrome with KCNJ2 mutations.
Topics: Administration, Oral; Adolescent; Adult; Andersen Syndrome; Anti-Arrhythmia Agents; Electrocardiogra | 2015 |
Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flut | 2007 |
Continuation of antiarrhythmic drugs, or arrhythmia surgery after multiple drug failures. A randomized trial in the treatment of postinfarction ventricular tachycardia.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Female; Flecainide; Humans; Male; Middle Aged; Propafenone; Sot | 1996 |
A multicentre, randomized trial on the benefit/risk profile of amiodarone, flecainide and propafenone in patients with cardiac disease and complex ventricular arrhythmias. Antiarrhythmic Drug Evaluation Group (A.D.E.G.).
Topics: Amiodarone; Cardiomyopathy, Dilated; Cardiomyopathy, Hypertrophic; Dose-Response Relationship, Drug; | 1992 |
105 other studies available for flecainide and Tachycardia, Ventricular
| Article | Year |
|---|---|
Safety and efficacy of flecainide associated with beta-blockers in arrhythmogenic right ventricular cardiomyopathy.
Topics: Arrhythmogenic Right Ventricular Dysplasia; Atrial Fibrillation; Defibrillators, Implantable; Flecai | 2022 |
Toxic Effects of Flecainide in a Patient With Kidney Failure and Tachyarrhythmia.
Topics: Aged; Atrial Flutter; Diagnosis, Differential; Dose-Response Relationship, Drug; Female; Flecainide; | 2021 |
Provocation Testing and Therapeutic Response in a Newly Described Channelopathy: RyR2 Calcium Release Deficiency Syndrome.
Topics: Animals; Arrhythmias, Cardiac; Calcium; Channelopathies; Death, Sudden, Cardiac; Flecainide; Humans; | 2022 |
Efficacy of flecainide in bidirectional ventricular tachycardia and tachycardia-induced cardiomyopathy with Andersen-Tawil syndrome.
Topics: Adolescent; Andersen Syndrome; Cardiomyopathies; Child; Female; Flecainide; Humans; Tachycardia; Tac | 2022 |
How does flecainide impact RyR2 channel function?
Topics: Anti-Arrhythmia Agents; Calcium; Flecainide; Humans; Myocytes, Cardiac; Ryanodine; Ryanodine Recepto | 2022 |
QTc Prolongation in Poison Center Exposures to CredibleMeds List of Substances with "Known Risk of Torsades de Pointes".
Topics: Amitriptyline; Arrhythmias, Cardiac; Diphenhydramine; Electrocardiography; Flecainide; Humans; Long | 2022 |
Diagnostic evaluation of unexplained ventricular tachyarrhythmias in younger adults.
Topics: Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Flecainide; Heart Arrest; Humans; Retro | 2023 |
The Feasibility and Safety of Flecainide Use Among Patients With Varying Degrees of Coronary Disease.
Topics: Coronary Artery Disease; Feasibility Studies; Flecainide; Humans; Retrospective Studies; Sotalol; Ta | 2023 |
Trans-2,3-enoyl-CoA reductase-like-related catecholaminergic polymorphic ventricular tachycardia with regular ventricular tachycardia and response to flecainide.
Topics: Anti-Arrhythmia Agents; Flecainide; Humans; Oxidoreductases; Ryanodine Receptor Calcium Release Chan | 2023 |
Personalized medicine in the dish to prevent calcium leak associated with short-coupled polymorphic ventricular tachycardia in patient-derived cardiomyocytes.
Topics: Anti-Arrhythmia Agents; Calcium; Flecainide; Humans; Myocytes, Cardiac; Precision Medicine; Proprano | 2023 |
Insights on the mechanism of flecainide in catecholaminergic polymorphic ventricular tachycardia.
Topics: Anti-Arrhythmia Agents; Calcium; Flecainide; Humans; Mutation; Ryanodine Receptor Calcium Release Ch | 2023 |
Co-Phenotype of Left Ventricular Non-Compaction Cardiomyopathy and Atypical Catecholaminergic Polymorphic Ventricular Tachycardia in Association With R169Q, a Ryanodine Receptor Type 2 Missense Mutation.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Calcium Signaling; Child; Child, Preschool; Dea | 2020 |
Ventricular arrhythmia suppression with ivabradine in a patient with catecholaminergic polymorphic ventricular tachycardia refractory to nadolol, flecainide, and sympathectomy.
Topics: Adolescent; Cardiovascular Agents; Electrocardiography; Exercise Test; Flecainide; Humans; Ivabradin | 2020 |
The Case of Flecainide Toxicity: What to Look for and How to Treat.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Female; Flecainide; Humans; Middle | 2020 |
VT or Not VT?: That Is the Question.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Flutter; Drug-Related Side Effects and Adverse Reactions; Elect | 2020 |
Catecholaminergic polymorphic ventricular tachycardia in pregnancy: a case report.
Topics: Death, Sudden, Cardiac; Female; Flecainide; Humans; Pregnancy; Ryanodine Receptor Calcium Release Ch | 2020 |
Fast and furious: flecainide toxicity presenting as monomorphic ventricular tachycardia.
Topics: Amiodarone; Electrocardiography; Female; Flecainide; Humans; Middle Aged; Tachycardia, Ventricular; | 2020 |
The Efficacy of Anti-Arrhythmic Drugs in Children With Idiopathic Frequent Symptomatic or Asymptomatic Premature Ventricular Complexes With or Without Asymptomatic Ventricular Tachycardia: a Retrospective Multi-Center Study.
Topics: Adolescent; Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Child; Child, Preschool; Female; Fl | 2021 |
Is the Debate on the Flecainide Action on the RYR2 in CPVT Closed?
Topics: Anti-Arrhythmia Agents; Flecainide; Humans; Ryanodine Receptor Calcium Release Channel; Tachycardia, | 2021 |
Sustained Wide Complex Tachycardia in a Healthy Man.
Topics: Adult; Anti-Arrhythmia Agents; Arrhythmogenic Right Ventricular Dysplasia; Bisoprolol; Defibrillator | 2021 |
Renal sympathetic denervation assisted treatment of electrical storm due to polymorphic ventricular tachycardia in a patient with cathecolaminergic polymorphic ventricular tachycardia.
Topics: Adrenergic beta-Antagonists; Adult; Anti-Arrhythmia Agents; Atenolol; Catheter Ablation; Electrocard | 2017 |
Flecainide Reduces Ventricular Arrhythmias in Patients With Genotype RyR2-positive Catecholaminergic Polymorphic Ventricular Tachycardia.
Topics: Adult; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; DNA Mutational Analysis; Electrocardiography; | 2018 |
An Irregular Wide Complex Tachycardia.
Topics: Action Potentials; Administration, Intravenous; Aged; Anti-Arrhythmia Agents; Electrocardiography; F | 2017 |
Neonatal complex arrhythmias possibly related to a TTN mutation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Bundle-Branch Block; Connectin; Electrocardiography; Fetal Monit | 2017 |
Efficacy of ivabradine to control ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia.
Topics: Adolescent; Anti-Arrhythmia Agents; Cardiovascular Agents; Electrocardiography; Exercise Test; Femal | 2018 |
Ventricular arrhythmia and death among atrial fibrillation patients using anti-arrhythmic drugs.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Cause of Death; Dronedarone; Female; Flecainide; | 2018 |
Can flecainide totally eliminate bidirectional ventricular tachycardia in pediatric patients with Andersen-Tawil syndrome?
Topics: Adolescent; Andersen Syndrome; Anti-Arrhythmia Agents; Child; Female; Flecainide; Humans; Tachycardi | 2018 |
Unusual Wide Complex Tachycardia During Rhythm Control for Atrial Fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Female; Flecainide; Heart Ra | 2018 |
Wide QRS Tachycardia in a Man With a Medical History of Atrial Fibrillation.
Topics: Aged; Atrial Fibrillation; Catheter Ablation; Electrocardiography; Flecainide; Heart Conduction Syst | 2019 |
A large deletion in RYR2 exon 3 is associated with nadolol and flecainide refractory catecholaminergic polymorphic ventricular tachycardia.
Topics: Adolescent; Anti-Arrhythmia Agents; Exons; Flecainide; Gene Deletion; Humans; Male; Nadolol; Ryanodi | 2019 |
An irregular, extremely broad QRS complex rhythm.
Topics: Accidental Falls; Aged; Anti-Arrhythmia Agents; Drug Overdose; Electrocardiography; Fatigue; Female; | 2019 |
Arrhythmogenic effect of flecainide toxicity.
Topics: Adenosine Triphosphate; Aged; Anti-Arrhythmia Agents; Bundle-Branch Block; Electrocardiography; Fema | 2013 |
HBI-3000 prevents secondary sudden cardiac death.
Topics: Animals; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Disease Models, Animal; Dogs; Dose-Response | 2013 |
Flecainide in CASQ2-mediated catecholaminergic polymorphic ventricular tachycardia: the gift that keeps on giving.
Topics: Calsequestrin; Death, Sudden, Cardiac; Exercise Test; Female; Flecainide; Humans; Male; Tachycardia, | 2013 |
Combination drug therapy for patients with intractable ventricular tachycardia associated with right ventricular cardiomyopathy.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmogenic Right Ventricular Dysplasia; Chronic Disease; Dr | 2014 |
A de novo novel cardiac ryanodine mutation (Ser4155Tyr) associated with catecholaminergic polymorphic ventricular tachycardia.
Topics: Adolescent; Anti-Arrhythmia Agents; Defibrillators, Implantable; Female; Flecainide; Follow-Up Studi | 2013 |
Effects of Na+ channel blockers on extrasystolic stimulation-evoked changes in ventricular conduction and repolarization.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrophysiological Pheno | 2014 |
Long-term conservative management of a giant cardiac fibroma.
Topics: Anti-Arrhythmia Agents; Disease Progression; Echocardiography; Female; Fibroma; Flecainide; Follow-U | 2013 |
Flecainide in patient with aggressive catecholaminergic polymorphic ventricular tachycardia due to novel RYR2 mutation.
Topics: Adult; Anti-Arrhythmia Agents; Electrocardiography; Flecainide; Humans; Male; Mutation; Ryanodine Re | 2014 |
An infant with a heartbreaking medication error.
Topics: Drug Overdose; Extracorporeal Membrane Oxygenation; Flecainide; Humans; Infant; Male; Medication Err | 2014 |
The mechanism of flecainide action in CPVT does not involve a direct effect on RyR2.
Topics: Animals; Anti-Arrhythmia Agents; Calcium Signaling; Dose-Response Relationship, Drug; Flecainide; HE | 2015 |
The direct actions of flecainide on the human cardiac ryanodine receptor: keeping open the debate on the mechanism of action of local anesthetics in CPVT.
Topics: Animals; Anti-Arrhythmia Agents; Flecainide; Humans; Male; Myocytes, Cardiac; Ryanodine Receptor Cal | 2015 |
Ablation of androgen receptor gene triggers right ventricular outflow tract ventricular tachycardia.
Topics: Action Potentials; Adenosine; Animals; Caffeine; Calcium; Flecainide; Gene Knockdown Techniques; Gen | 2015 |
Right ventricular outflow tract tachycardia worsened during pregnancy.
Topics: Adult; Anti-Arrhythmia Agents; Catheter Ablation; Drug Therapy, Combination; Female; Flecainide; Hos | 2015 |
Diagnostic Approach to Unexplained Cardiac Arrest (from the FIVI-Gen Study).
Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Brugada Syndrome; Cardiac Catheteri | 2015 |
Brugada Syndrome Phenotype Elimination by Epicardial Substrate Ablation.
Topics: Action Potentials; Adult; Anti-Arrhythmia Agents; Brugada Syndrome; Catheter Ablation; Death, Sudden | 2015 |
Flecainide monotherapy is an option for selected patients with catecholaminergic polymorphic ventricular tachycardia intolerant of β-blockade.
Topics: Adrenergic beta-Antagonists; Adult; Anti-Arrhythmia Agents; Dose-Response Relationship, Drug; Drug M | 2016 |
Flecainide monotherapy for catecholaminergic polymorphic ventricular tachycardia: Perspectives and limitations.
Topics: Anti-Arrhythmia Agents; Flecainide; Humans; Tachycardia; Tachycardia, Ventricular | 2016 |
In silico prediction of drug therapy in catecholaminergic polymorphic ventricular tachycardia.
Topics: Animals; Animals, Genetically Modified; Anti-Arrhythmia Agents; Electrocardiography; Flecainide; Mic | 2016 |
Clinical and genetic profile of catecholaminergic polymorphic ventricular tachycardia in Hong Kong Chinese children.
Topics: Adolescent; Child; Defibrillators, Implantable; Female; Flecainide; Humans; Male; Tachycardia, Ventr | 2016 |
A human pluripotent stem cell model of catecholaminergic polymorphic ventricular tachycardia recapitulates patient-specific drug responses.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Biomarkers; Calcium; Calcium Signaling; Catechola | 2016 |
Eleclazine, an inhibitor of the cardiac late sodium current, is superior to flecainide in suppressing catecholamine-induced ventricular tachycardia and T-wave alternans in an intact porcine model.
Topics: Administration, Intravenous; Animals; Catecholamines; Disease Models, Animal; Drug Monitoring; Elect | 2017 |
Questioning flecainide's mechanism of action in the treatment of catecholaminergic polymorphic ventricular tachycardia.
Topics: Electrocardiography; Flecainide; Humans; Tachycardia, Ventricular | 2016 |
A dangerous secret.
Topics: Adolescent; Anti-Arrhythmia Agents; Diagnosis, Differential; Drug Overdose; Electrocardiography; Fle | 2009 |
Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Calcium; Child; Flecainide; Heart Rate; Human | 2009 |
Paroxysmal bidirectional ventricular tachycardia with tachycardiomyopathy in a pregnant woman.
Topics: Adrenergic beta-Antagonists; Adult; Anti-Arrhythmia Agents; Bisoprolol; Cesarean Section; Female; Fl | 2009 |
Tpeak-Tend interval and Tpeak-Tend/QT ratio as markers of ventricular tachycardia inducibility in subjects with Brugada ECG phenotype.
Topics: Adult; Ajmaline; Anti-Arrhythmia Agents; Biomarkers; Brugada Syndrome; Electrocardiography; Female; | 2010 |
Predicting drug-induced slowing of conduction and pro-arrhythmia: identifying the 'bad' sodium current blockers.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; CHO Cells; Cricetinae; Cricetulus; Drug Evalu | 2010 |
Efficacy of flecainide in a patient with catecholaminergic polymorphic ventricular tachycardia.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Anti-Arrhythmia Agents; Bisoprolol; Dose-Response Rel | 2011 |
Catecholaminergic polymorphic ventricular tachycardia: important messages from case reports.
Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Calcium Channel Blockers; Catecholamin | 2011 |
Biophysical and molecular characterization of a novel de novo KCNJ2 mutation associated with Andersen-Tawil syndrome and catecholaminergic polymorphic ventricular tachycardia mimicry.
Topics: Amino Acid Sequence; Amino Acid Substitution; Andersen Syndrome; Arrhythmias, Cardiac; Base Sequence | 2011 |
Na+ channel distribution and electrophysiological heterogeneities in guinea pig ventricular wall.
Topics: Action Potentials; Animals; Electrocardiography; Flecainide; Guinea Pigs; Heart Conduction System; M | 2011 |
Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia.
Topics: Analysis of Variance; Animals; Anti-Arrhythmia Agents; Calcium Channel Blockers; Calsequestrin; Defi | 2011 |
Mapping of reentrant spontaneous polymorphic ventricular tachycardia in a Scn5a+/- mouse model.
Topics: Animals; Anti-Arrhythmia Agents; Brugada Syndrome; Disease Models, Animal; Electrocardiography; Elec | 2011 |
Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Child; Defibrillators, Implan | 2011 |
Short communication: flecainide exerts an antiarrhythmic effect in a mouse model of catecholaminergic polymorphic ventricular tachycardia by increasing the threshold for triggered activity.
Topics: Animals; Anti-Arrhythmia Agents; Calcium Signaling; Disease Models, Animal; Extracellular Space; Fle | 2011 |
Postpacing abnormal repolarization in catecholaminergic polymorphic ventricular tachycardia associated with a mutation in the cardiac ryanodine receptor gene.
Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Catheter Ablation; Child; Dea | 2011 |
Efficacy and potency of class I antiarrhythmic drugs for suppression of Ca2+ waves in permeabilized myocytes lacking calsequestrin.
Topics: Animals; Anti-Arrhythmia Agents; Calcium; Calcium Signaling; Calsequestrin; Cell Membrane Permeabili | 2011 |
Mechanism of antiarrhythmic effects of flecainide in catecholaminergic polymorphic ventricular tachycardia.
Topics: Animals; Anti-Arrhythmia Agents; Flecainide; Ryanodine Receptor Calcium Release Channel; Tachycardia | 2011 |
Flecainide suppresses defibrillator-induced storming in catecholaminergic polymorphic ventricular tachycardia.
Topics: Adolescent; Anti-Arrhythmia Agents; Defibrillators, Implantable; Flecainide; Humans; Male; Tachycard | 2012 |
Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Anti-Arrhythmia Agents; Child; Cohort Studies; Elect | 2013 |
Transplacental flecainide therapy in the treatment of fetal supraventricular tachycardia.
Topics: Adult; Anti-Arrhythmia Agents; Cardiotocography; Electrocardiography; Female; Fetal Diseases; Flecai | 2002 |
Flecainide test in Brugada syndrome: a reproducible but risky tool.
Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Bundle-Branch Block; Death, Sudden, Cardiac; Electrocardi | 2003 |
Flecainide induced ventricular fibrillation in a neonate.
Topics: Anti-Arrhythmia Agents; Fatal Outcome; Flecainide; Humans; Infant, Newborn; Tachycardia, Supraventri | 2003 |
Delay in right ventricular activation contributes to Brugada syndrome.
Topics: Action Potentials; Adult; Anti-Arrhythmia Agents; Calcium Channels, L-Type; Echocardiography, Dopple | 2004 |
Differentiation of the electrophysiological effects on the atrial myocardium between the pure Na channel blocker, pilsicainide, and flecainide.
Topics: Adult; Anti-Arrhythmia Agents; Atrial Flutter; Electrocardiography; Electrophysiologic Techniques, C | 2004 |
Clinical and electrophysiologic profile of Brugada syndrome in Iranian patients.
Topics: Adult; Anti-Arrhythmia Agents; Bundle-Branch Block; Defibrillators, Implantable; Electric Stimulatio | 2005 |
[Life-threatening ventricular tachycardia during flecainide treatment for symptomatic atrial fibrillation in a patient with a structural cardiac disorder].
Topics: Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Flecainide; Humans; Male; T | 2006 |
Flecainide for recurrent malignant ventricular arrhythmias in two siblings with Andersen-Tawil syndrome.
Topics: Andersen Syndrome; Anti-Arrhythmia Agents; Child; Child, Preschool; Defibrillators, Implantable; Fem | 2007 |
Flecainide suppresses bidirectional ventricular tachycardia and reverses tachycardia-induced cardiomyopathy in Andersen-Tawil syndrome.
Topics: Adolescent; Andersen Syndrome; Anti-Arrhythmia Agents; Cardiomyopathies; Female; Flecainide; Humans; | 2008 |
Malignant arrhythmias and acute myocardial ischemia: interaction between flecainide and the autonomic nervous system.
Topics: Animals; Autonomic Nervous System; Cardiac Complexes, Premature; Cats; Electrocardiography; Flecaini | 1994 |
Determinants and mechanisms of flecainide-induced promotion of ventricular tachycardia in anesthetized dogs.
Topics: Animals; Cardiac Pacing, Artificial; Dogs; Dose-Response Relationship, Drug; Electrocardiography; Fl | 1995 |
Efficacy and safety of combination therapy with amiodarone and type I agents for treatment of inducible ventricular tachycardia.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Drug Therapy, Combinati | 1993 |
Electrophysiological effects of flecainide on anisotropic conduction and reentry in infarcted canine hearts.
Topics: Animals; Anisotropy; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Dogs; Electrocardiography; El | 1995 |
Reversal of flecainide-induced ventricular arrhythmia by hypertonic sodium bicarbonate in dogs.
Topics: Animals; Cardiac Pacing, Artificial; Disease Models, Animal; Dogs; Electrocardiography; Flecainide; | 1995 |
Reentrant arrhythmias in the subacute infarction period. The proarrhythmic effect of flecainide acetate on functional reentrant circuits.
Topics: Animals; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Death, Sudden, Cardiac; Dogs; Electrocard | 1995 |
Flecainide and amiodarone: combined therapy for refractory tachyarrhythmias in infancy.
Topics: Amiodarone; Drug Therapy, Combination; Electrocardiography, Ambulatory; Female; Flecainide; Follow-U | 1995 |
Successful use of flecainide to treat new onset maternal ventricular tachycardia in pregnancy.
Topics: Adult; Electrocardiography; Female; Flecainide; Heart; Humans; Pregnancy; Pregnancy Complications, C | 1994 |
Pleomorphic ventricular tachycardia with antegrade His-bundle activation: elucidation by multiple His-bundle recordings.
Topics: Anti-Arrhythmia Agents; Bundle of His; Cardiac Pacing, Artificial; Electrocardiography; Electrophysi | 1994 |
[Tachycardia with wide QRS. Limitations of electrocardiographic criteria in patients treated with anti-arrhythmia agents].
Topics: Anti-Arrhythmia Agents; Diagnosis, Differential; Electrocardiography; Flecainide; Humans; Male; Midd | 1994 |
Flecainide-induced JT prolongation, T wave inversion and ventricular tachycardia during treatment for symptomatic atrial fibrillation.
Topics: Aged; Atrial Fibrillation; Electric Countershock; Electrocardiography; Female; Flecainide; Heart Con | 1994 |
Treatment with flecainide for symptomatic and refractory tachyarrhythmias in children.
Topics: Administration, Oral; Adolescent; Child; Child, Preschool; Female; Flecainide; Humans; Infant; Injec | 1994 |
Effect of E-4031, a new class III antiarrhythmic drug, on reentrant ventricular arrhythmias: comparison with conventional class I drugs.
Topics: Animals; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Disease Models, Animal; Disopyrami | 1993 |
Efficacy of class 1C antiarrhythmic agents in patients with inducible ventricular tachycardia refractory to therapy with class 1A antiarrhythmic drugs.
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Benzeneacetamides; Electric Stimulation; Enc | 1993 |
Use-dependent prolongation of ventricular tachycardia cycle length by type I antiarrhythmic drugs in humans.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Electrocardiography; Female; Flecainide; Humans; Lidocaine; Mal | 1993 |
Effects of verapamil in ventricular tachycardias. An experimental and clinical study.
Topics: Aconitine; Adult; Animals; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Dogs; Electrocardiogr | 1997 |
Survival in a case of life-threatening flecainide overdose.
Topics: Adolescent; Anti-Arrhythmia Agents; Bradycardia; Creatine Kinase; Drug Overdose; Electrocardiography | 1998 |
Class IC antiarrhythmic drugs, flecainide and pilsicainide, produce ST segment elevation simulating inferior myocardial ischemia.
Topics: Anti-Arrhythmia Agents; Diagnosis, Differential; Drug Therapy, Combination; Electrocardiography; Fle | 1998 |
ST segment elevation in the right precordial leads induced with class IC antiarrhythmic drugs: insight into the mechanism of Brugada syndrome.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Flecainide; Follow-Up Studies; Hea | 1999 |
Arrhythmic disorder mapped to chromosome 1q42-q43 causes malignant polymorphic ventricular tachycardia in structurally normal hearts.
Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Biopsy; Child; Chromosome Aberrations; Chromosome Disorde | 1999 |
His-Purkinje system reentry as a proarrhythmic effect of flecainide.
Topics: Administration, Oral; Aged; Ajmaline; Anti-Arrhythmia Agents; Bundle of His; Bundle-Branch Block; El | 2000 |
Anisotropic effects of sodium channel blockers on the wavelength for ventricular excitation in dogs.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disopyramide; Dogs; Electr | 2000 |
Idiopathic sustained left ventricular tachycardia in pediatric patients.
Topics: Adolescent; Anti-Arrhythmia Agents; Child; Child, Preschool; Electrophysiology; Female; Flecainide; | 2001 |
Autonomic effects of antiarrhythmic drugs and their importance.
Topics: Adult; Autonomic Nervous System; Cardiac Complexes, Premature; Electrocardiography; Female; Flecaini | 1992 |
Efficacy of flecainide, sotalol, and verapamil in the treatment of right ventricular tachycardia in patients without overt cardiac abnormality.
Topics: Adult; Aged; Electric Stimulation; Exercise Test; Flecainide; Humans; Male; Middle Aged; Sotalol; Ta | 1992 |